The DOI matches its Crossref record; 826 of the 826 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Open accessAbstract
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
(1985) · Cited by 2,882
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695 · cited 1×
“Patients with anxiety disorders are frequent users of emergency medical services (Klerman et al. 1991; Wang et al. 2005), are at a high risk for suicide attempts (Weissman et al.”
Background
Research works printed but not linked: 116
- Altshuler LL, 2001, Postgrad Med, 1
- Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 435, 10.1002/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B · doi:10.1002/(sici)1099-1077(199908)14:6<435::aid-hup109>3.0.co;2-b
- Bakish D, 1996, Psychopharmacol Bull, 32, 135
- Ballenger JC, 2001, J Clin Psychiatry, 62, 53
- Bandelow B, 2004, Br J Psychiatry, 184, 271, 10.1192/bjp.184.3.271 · DOI
- Bandelow B, 2002, Eur Neuropsychopharmacol, 12, S364, 10.1016/S0924-977X(02)80585-5 · doi:10.1016/s0924-977x(02)80585-5
- Bradwejn J, 1993, Can J Psychiatry, 38, S109
- Braun P, 1990, J Clin Psychiatry, 51, 236
- Bystritsky A, 2008, Psychopharmacol Bull, 41, 46
- 10.3109/10401239909147053 · doi:10.3109/10401239909147053
- Chao IL, 2004, Pharmacopsychiatry, 37, 239, 10.1055/s-2004-832600 · DOI
- Charney DS, 1989, J Clin Psychiatry, 50, 418
- Charney DS, 1986, J Clin Psychiatry, 47, 580
- Chouinard G, 1990, Psychopharmacol Bull, 26, 279
- 10.3109/10401230490281609 · doi:10.3109/10401230490281609
- Davis LL, 2008, Psychopharmacol Bull, 41, 8
- DeVeaugh-Geiss J, 1989, Psychopharmacol Bull, 25, 36
- Dieleman GC, 2008, Tijdschr Psychiatr, 50, 43
- Dunner DL, 1986, J Clin Psychiatry, 47, 458
- Eriksson T, 2007, Int Clin Psychopharmacol, 22, 57
- Feighner JP, 1987, J Clin Psychiatry (Suppl), 48, 3
- Feighner JP, 1982, J Clin Psychiatry, 43, 103
- Feltner DE, 2003, J Clin Psychopharmacol, 23, 240
- Ferreri M, 1994, Encéphale, 20, 785
- 10.1037/0022-006X.65.6.1026 · doi:10.1037/0022-006x.65.6.1026
- Fesler FA, 1991, J Clin Psychiatry, 52, 361
- Foa EB, 2000, J Clin Psychiatry, 61, 43
- Frommberger U, 2004, Fortschr Neurol Psychiatr, 72, 411, 10.1055/s-2004-818455 · doi:10.1055/s-2004-818455
- Gelpin E, 1996, J Clin Psychiatry, 57, 390
- Gruber RP, 1971, Dis Nerv Syst, 32, 180
- Hamner MB, 2001, Ann Clin Psychiatry, 13, 141, 10.3109/10401230109148960 · DOI
- 10.3109/10401230009147096 · DOI · Paper page
- Hoehn-Saric R, 1988, J Clin Psychiatry, 49, 293
- Hoffart A, 1993, J Clin Psychiatry, 54, 481
- 10.1037/0022-006X.72.3.393 · DOI
- Hofmann SG, 2008, J Clin Psychiatry, e1
- Husain MM, 1993, Am J Psychiatry, 150, 1899
- Jenike MA, 1991, J Clin Psychiatry, 52, 13
- Khanna S, 1988, Convuls Ther, 4, 314
- Klerman GL, 199, Social Morbidity Health Care Utilization J, 265, 742
- Kocabasoglu N, 2004, Eur Neuropsychopharmacol, 14, S304, 10.1016/S0924-977X(04)80382-1 · doi:10.1016/s0924-977x(04)80382-1
- Koran LM, 2007, Am J Psychiatry, 164, 5
- Lee C, 2002, J Clin Psychol Psychother, 58, 1071
- Lenox-Smith AJ, 2003, Br J Gen Pract, 53, 772
- Li D, 2001, J Psychiatry Neurosci, 26, 190
- Lidren DM, 1994, J Consult Clin Psychol, 62, 865, 10.1037/0022-006X.62.4.865 · DOI · Paper page
- Liebowitz MR, 1988, J Clin Psychiatry, 49, 252
- 10.1002/(SICI)1520-6394(1999)10:3%3C89::AID-DA1%3E3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
- Livingston MG, 1994, Br J Hosp Med, 51, 281
- Lopes AC, 2008, Biol Psychiaty, 63, 131s, 10.1016/j.biopsych.2007.11.007 · doi:10.1016/j.biopsych.2007.11.007
- López-Ibor JJ, 1975, Neurological treatment in psychiatry, pain and epilepsy, 151
- Lum M, 1990, Biol Psychiatry :A, 27, 164
- Maletzky B, 1994, Convuls Ther, 10, 34
- Marazziti D, 1999, Am J Psychiatry, 156, 1834, 10.1176/ajp.156.11.1834-a · doi:10.1176/ajp.156.11.1834-a
- Marmar CR, 1996, J Clin Psychiatry, 57, 66
- Mavissakalian M, 1983, Psychopharmacol Bull, 19, 116
- Mavissakalian M, 1986, J Clin Psychol, 47, 117
- Meibach RC, 1987, J Clin Psychiatry, 48, 355
- Misri S, 2000, Can Family Phys, 46, 626
- Mohlman J, 2003, Am J Geriatr Psychiatry, 11, 24
- Montoya A, 2002, Neurosurgery, 50, 1043
- Munjack DJ, 1989, J Clin Psychopharmacol, 9, 22
- Munjack DJ, 1990, J Clin Psychiatry, 51, 35
- Nelson J, 1999, Can Soc Clin Pharmacol, 6, 69
- Neylan TC, 2006, Am J Psychiatry, 163, 2186, 10.1176/ajp.2006.163.12.2186 · doi:10.1176/ajp.2006.163.12.2186
- Nicolini H, 2008, Psychol Med, 1
- NIMH 1976. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy E, ECDEU Assessment manual for psychopharmacology. Revised edition. Rockville, MD: NIMH. p 217–222.
- Noyes R, 1996, J Clin Psychiatry, 57, 349
- Nutt DJ, 1998, J Clin Psychiatry, 59, 4
- Ontiveros A, 1992, J Psychiatry Neurosci, 17, 78
- Pastrana Jiménez JI, 2007, Actas Esp Psiquiatr, 35, 351
- Pigott TA, 1992, J Clin Psychopharmacol, 12, 11
- Pollack MH, 2003, Psychopharmacol Bull, 37, 53
- Pollack MH, 1994, J Clin Psychiatry, 55, 200
- Pollack MH, 1996, Psychopharmacol Bull, 32, 667
- Pollack MH, 1997, J Clin Psychiatry, 58, 19
- Pols H, 1993, Acta Psychiatr Belg, 93, 169
- Power KG, 1990, Br J Gen Pract, 40, 289
- Prasko J, 2006, Neuroendocrinol Lett, 27, 473
- Prasko J, 2006, Neuroendocrinol Lett, 27, 327
- 10.1034/j.1600-0447.2001.00263.x · DOI · Paper page
- Ravizza L, 1996, Psychopharmacol Bull, 32, 677
- 10.1037/0022-006X.70.4.86 · doi:10.1037/0022-006x.70.4.86
- Rickels K, 1982, J Clin Psychiatry, 43, 81
- Riddle MA, 1996, Psychopharmacol Bull, 32, 399
- Rizley R, 1986, Psychopharmacol Bull, 22, 167
- Rothbaum B, 1997, Bull Menninger Clinic, 61, 317
- Rothbaum BO, 2008, J Clin Psychiatry, e1
- Rück C, 2006, Capsulotomy in anxiety disorders [thesis]
- 10.1176/appi.ajp.164.2.290 · DOI
- 10.1002/da.20271 · DOI
- Sachdev P, 1995, J Nerv Ment Dis, 183, 408, 10.1097/00005053-199506000-00010 · doi:10.1097/00005053-199506000-00010
- 10.1345/aph.1C040 · doi:10.1345/aph.1c040 · Paper page
- Saxena S, 1996, J Clin Psychiatry, 57, 303
- Seedat S, 2004, J Clin Psychiatry, 65, 244
- Shader RI, 1993, New Engl J Med, 13, 1398
- Sharp DM, 1997, Br J Gen Pract, 47, 150
- Simon NM, 2003, Psychopharmacol Bull, 37, 66
- Simon NM, 2008, J Clin Psychiatry, e1
- Stein DJ, 1999, S Afr Med J, 89, 402
- 10.3109/10401230600948431 · doi:10.3109/10401230600948431
- Stein DJ, 2007, Eur Neuropsychophar17(Suppl, 4, S509, 10.1016/S0924-977X(07)70784-8 · doi:10.1016/s0924-977x(07)70784-8
- Strand M, 1990, J Clin Psychiatry (Suppl), 51, 40
- Telch MJ, 1995, J Consult Clin Psychol, 63, 823, 10.1037/0022-006X.63.5.823 · doi:10.1037/0022-006x.63.5.823
- Tesar GE, 1991, J Clin Psychiatry, 52, 69
- Tiffon L, 1994, J Clin Psychiatry, 55, 66
- Todorov C, 2000, Can J Psychiatry, 45, 257, 10.1177/070674370004500304 · doi:10.1177/070674370004500304
- Turner SM, 1994, J Consult Clin Psychol, 62, 350, 10.1037/0022-006X.62.2.350 · DOI · Paper page
- van Ameringen M, 1993, J Clin Psychiatry, 54, 27
- van der Kolk BA, 1994, J Clin Psychiatry, 55, 517
- Wetherell JL, 2003, J Consult Clin Psychol, 71, 31, 10.1037/0022-006X.71.1.31 · DOI · Paper page
- WHO, 1991, Clinical Descriptions and Diagnostic Guidelines
- Woodman CL, 1994, J Clin Psychiatry, 55, 134
- Worthington JJ, 1998, Psychopharmacol Bull, 34, 199
- Zitterl W, 1999, Wien Klin Wochenschr, 111, 439
- Zohar J, 2006, Obsessive-compulsive disorder and comorbidity, 79
Cited by
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
Self-citationStein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Self-citationObsessive-compulsive disorder: An integrative genetic and neurobiological perspective
Pauls, D. L., Abramovitch, A., Rauch, S. L., & Geller, D. A. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3746 · Cited by 793
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Self-citationSerotonin control of sleep-wake behavior
Monti, J. M. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.11.003 · Cited by 614
Domschke, K., Stevens, S., Pfleiderer, B., & Gerlach, A. L. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.08.008 · Cited by 580
Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
Self-citationTyrer, P., & Baldwin, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69865-6 · Cited by 404
Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD
Greenberg, B. D., Rauch, S. L., & Haber, S. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.128 · Cited by 359
The Serotonin-1A Receptor in Anxiety Disorders
Akimova, E., Lanzenberger, R., & Kasper, S. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.012 · Cited by 360
Self-citationStein, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09620-4 · Cited by 352
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationManifesto for a European research network into Problematic Usage of the Internet
Fineberg, N., Demetrovics, Z., Stein, D., Ioannidis, K., Potenza, M., Grünblatt, E., Brand, M., Billieux, J., Carmi, L., King, D., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.08.004 · Cited by 334
Self-citationTranslocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects
Rupprecht, R., Rammes, G., Eser, D., Baghai, T. C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H. O., Chaperon, F., et al. (2009) · Science · doi:10.1126/science.1175055 · Cited by 328
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289
Warnke, A. (2014) · Psychiatric Drugs in Children and Adolescents · doi:10.1007/978-3-7091-1501-5_11 · Cited by 286
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Reduction of PTSD symptoms with pre-reactivation propranolol therapy: A randomized controlled trial
Brunet, A., Saumier, D., Liu, A., Streiner, D. L., Tremblay, J., & Pitman, R. K. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17050481 · Cited by 256
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Nicolas, L. B., Kolb, Y., & Prinssen, E. P. M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.015 · Cited by 234
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges
Koyuncu, A., İnce, E., Ertekin, E., & Tükel, R. (2019) · Drugs in Context · doi:10.7573/dic.212573 · Cited by 216
Berlim, M. T., Neufeld, N. H., & Van den Eynde, F. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.022 · Cited by 219
Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)
Ipser, J. C., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001209 · Cited by 216
Should OCD be classified as an anxiety disorder in DSM-V?
Stein, D. J., Fineberg, N. A., Bienvenu, O. J., Denys, D., Lochner, C., Nestadt, G., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2010) · Depression and Anxiety · doi:10.1002/da.20699 · Cited by 212
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Self-citationDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
Aigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
“In conclusion, there is no clear evidence for the general use of SSRIs (citalopram, fl uoxetine, sertraline) in anorexia nervosa.”
BackgroundMethodInfluentialBauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Self-citationA Review of Alprazolam Use, Misuse, and Withdrawal
Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000350 · Cited by 195
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“…a similar rigorous hierarchy of evidence and level of recommendation as was used in previous WFSBP guidelines including the first published WFSBP Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders (Bandelow et al. 2008) (see Table 2).”
MethodInfluentialSelf-citationBiological markers of generalized anxiety disorder
Maron, E., & Nutt, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/dnutt · Cited by 164
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Compulsive sexual behavior and dysregulation of emotion
Lew-Starowicz, M., Lewczuk, K., Nowakowska, I., Kraus, S., & Gola, M. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.10.003 · Cited by 163
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Self-citationBandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationClinical practice guidelines for Obsessive-Compulsive Disorder
Janardhan Reddy, Y., Sundar, A., Narayanaswamy, J., & Math, S. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196976 · Cited by 156
Batelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M., & van Balkom, A. J. L. M. (2017) · BMJ · doi:10.1136/bmj.j3927 · Cited by 153
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Reinholt, N., & Krogh, J. (2014) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2014.897367 · Cited by 146
Grant, J. E. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1402176 · Cited by 148
Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117705089 · Cited by 144
Virtual reality exposure in anxiety disorders: Impact on psychophysiological reactivity
Diemer, J., Mühlberger, A., Pauli, P., & Zwanzger, P. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.892632 · Cited by 146
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Self-citationDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv047 · Cited by 134
“However, due to their favorable risk profile, preference should be given to the selective serotonin reuptake inhibitors (Bandelow et al., 2008; Bandelow et al., 2012; Koran and Simpson, 2013; Baldwin et al., 2014).”
BackgroundSelf-citationDold, M., Bartova, L., Souery, D., Mendlewicz, J., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., & Kasper, S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.020 · Cited by 131
Self-citationCurrent Considerations in the Treatment of Generalized Anxiety Disorder
Katzman, M. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923020-00002 · Cited by 128
What does a transdiagnostic approach have to offer the treatment of anxiety disorders?
McManus, F., Shafran, R., & Cooper, Z. (2010) · British Journal of Clinical Psychology · doi:10.1348/014466509x476567 · Cited by 128
Abramovitch, A., Dar, R., Mittelman, A., & Wilhelm, S. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000050 · Cited by 120
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Hollander, E., Stein, D. J., Fineberg, N. A., Marteau, F., & Legault, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05911blu · Cited by 115
Self-citationBruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
The use of waitlists as control conditions in anxiety disorders research
Patterson, B., Boyle, M. H., Kivlenieks, M., & Van Ameringen, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.08.015 · Cited by 94
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
The German Guidelines for the treatment of anxiety disorders: first revision
Bandelow, B., Werner, A. M., Kopp, I., Rudolf, S., Wiltink, J., & Beutel, M. E. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01324-1 · Cited by 90
Self-citationAlbert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
No end in sight: benzodiazepine use in older adults in the United States.
Maust, D. T., Kales, H. C., Wiechers, I. R., Blow, F. C., & Olfson, M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14379 · Cited by 82
“In addition to psychotherapy as an alternative to benzodiazepines, selective-serotonin reuptake inhibitors are considered first-line pharmacotherapy for anxiety disorders.(33,34) Among all benzodiazepine visits, just one-quarter of individuals were taking an antidepressant.”
BackgroundGloster, A. T., Sonntag, R., Hoyer, J., Meyer, A. H., Heinze, S., Ströhle, A., Eifert, G., & Wittchen, H.-U. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370162 · Cited by 88
Belotto-Silva, C., Diniz, J. B., Malavazzi, D. M., Valério, C., Fossaluza, V., Borcato, S., Seixas, A. A., Morelli, D., Miguel, E. C., & Shavitt, R. G. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.08.008 · Cited by 85
Dold, M., Bartova, L., Fugger, G., Kautzky, A., Souery, D., Mendlewicz, J., Papadimitriou, G. N., Dikeos, D., Ferentinos, P., Porcelli, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy009 · Cited by 82
Self-citationPharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Lusicic, A., Schruers, K. R., Pallanti, S., & Castle, D. J. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s121140 · Cited by 81
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Hollander, E., Kasper, S., Möller, H.-J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086296 · Cited by 84
Self-citationBosman, R. C., Huijbregts, K. M., Verhaak, P. F., Ruhé, H. G., van Marwijk, H. W., van Balkom, A. J., & Batelaan, N. M. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x686641 · Cited by 76
Bandelow, B., Sagebiel, A., Belz, M., Görlich, Y., Michaelis, S., & Wedekind, D. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.49 · Cited by 70
Self-citationBaldwin, D. S., Allgulander, C., Bandelow, B., Ferre, F., & Pallanti, S. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.624548 · Cited by 69
Self-citationAgomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Evidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
Schizo-obsessive spectrum disorders: an update
Scotti-Muzzi, E., & Saide, O. L. (2017) · CNS Spectrums · doi:10.1017/s1092852916000390 · Cited by 65
Dold, M., Kautzky, A., Bartova, L., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.005 · Cited by 66
“, sleep disturbances), or due to concomitant anxiety symptoms (Bandelow et al., 2008).”
Self-citationA 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Van Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
Self-citationAligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“They consisted of eight narrative reviews (Bakker, Van Balkom, & Stein, 2005; Bandelow et al., 2008; Bystritsky, 2006; Chen & Tsai, 2016; Holt & Lydiard, 2007; Lorenz, Jackson, & Saitz, 2010; Pollack, 2009; Starcevic, 2008), five systematic reviews (Barton et al., 2014; Cosci & Fava, 2013; Ipser et…”
MethodWilliams, T., McCaul, M., Schwarzer, G., Cipriani, A., Stein, D. J., & Ipser, J. (2020) · Acta Neuropsychiatrica · doi:10.1017/neu.2020.6 · Cited by 59
“…reviews and meta-analyses in identifying that SSRIs like paroxetine are first-line agents for the treatment of SAD (Ballenger et al., 1998; Bandelow et al., 2002; Bandelow et al., 2012; Bandelow & Michaelis, 2015; Blanco et al., 2003; Van der Linden et al., 2000), aside from documented…”
BackgroundAlbert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Self-citationKraus, C., Ganger, S., Losak, J., Hahn, A., Savli, M., Kranz, G. S., Baldinger, P., Windischberger, C., Kasper, S., & Lanzenberger, R. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.036 · Cited by 54
Self-citationTreating treatment non-responders: A meta-analysis of randomized controlled psychotherapy trials
Gloster, A. T., Rinner, M. T. B., Ioannou, M., Villanueva, J., Block, V. J., Ferrari, G., Benoy, C., Bader, K., & Karekla, M. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2019.101810 · Cited by 53
Treatment–resistant panic disorder: a systematic review
Freire, R. C., Zugliani, M. M., Garcia, R. F., & Nardi, A. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109628 · Cited by 47
Domschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
Self-citationBiological Markers of Generalized Anxiety Disorder
Maron, E., & Nutt, D. (2018) · Focus · doi:10.1176/appi.focus.16205 · Cited by 42
Ninomiya, A., Sado, M., Park, S., Fujisawa, D., Kosugi, T., Nakagawa, A., Shirahase, J., & Mimura, M. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12960 · Cited by 42
Comprehensive review of generalized anxiety disorder in primary care in Europe.
Parmentier, H., García-Campayo, J., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.770731 · Cited by 37
Bachhuber, M. A., Maughan, B. C., Mitra, N., Feingold, J., & Starrels, J. L. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.08.005 · Cited by 35
Scholten, W. D., Batelaan, N. M., van Oppen, P., Smit, J. H., Hoogendoorn, A. W., van Megen, H. J. G. M., Cath, D. C., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489498 · Cited by 33
Xenon in the treatment of panic disorder: An open label study
Dobrovolsky, A., Ichim, T. E., Ma, D., Kesari, S., & Bogin, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1237-1 · Cited by 34
Davies, S. J., Rudoler, D., de Oliveira, C., Huang, A., Kurdyak, P., & Iaboni, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069096 · Cited by 32
“…short- or long-term benzodiazepine use is a reasonable option for symptom management, weighing up the risks and benefits on a case-by-case basis, as is advocated by some current guidelines (Baldwin et al., 2013; Baldwin et al., 2014; Bandelow et al., 2008; Canadian Psychiatric Association, 2006).”
BackgroundChronic diazepam administration increases the expression of Lcn2 in the CNS
Furukawa, T., Shimoyama, S., Miki, Y., Nikaido, Y., Koga, K., Nakamura, K., Wakabayashi, K., & Ueno, S. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.283 · Cited by 31
“Benzodiazepines (BZDs) are clinically used to treat anxiety, insomnia, and some forms of epilepsy and as adjunct treatments in both depressive disorder and schizophrenia (Bandelow et al. 2008; Rudolph and Knoflach, 2011; Volz et al. 2007).”
BackgroundBrandt, J., Alkabanni, W., Alessi-Severini, S., & Leong, C. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0648-y · Cited by 27
Trkulja, V., & Barić, H. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_22 · Cited by 28
Metadata
- Authors
- Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP TASK FORCE ON TREATMENT GUIDE
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 9
- Issue
- 4
- Pages
- 248-312
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W1966065460
- Cited by
- 854
- References
- 826
- FWCI
- 73.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.